Signals mentioning OZiva
- HUL targets 22-24% EBITDA margin, raises capex to 3% of turnover
- HUL raises productive capex target to 3% of turnover to fund growth and premiumisation
- HUL raises productive capex to 3% of turnover to accelerate premium growth
- HUL to lift productive capex to 3% of turnover, targets bolt-on acquisitions
- India’s health-supplements sector draws $72m as investors back larger, selective bets
- India’s supplements sector draws $70M as investors back scalable D2C brands
- HUL posts strongest quarterly growth in 13 quarters, with Q1 turnover of ₹17,184 crore
- Marico, HUL turn digital-first acquisitions into wider retail-growth engines
- Peptide, collagen supplements surge in India as experts flag thin evidence behind the hype
- Supply6 Raises ₹48 Cr Led By Unilever Ventures To Widen Portfolio And Enter New Markets
- HUL names ex-Marico, Flipkart exec Koteshwar LN as Oziva CEO
- HUL names ex-Marico, Flipkart exec Koteshwar LN as Oziva CEO to lead wellness push
- Honasa buys 58% of Fluence Pharma for Rs 135 cr, launches Honasa Health to enter VMS market
- Honasa slips 3% after ₹135 cr Fluence Pharma deal to enter nutraceuticals
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals category
- Why HUL, Marico, ITC and L'Oréal are buying India's D2C darlings
- TruNativ lands $30M Series B from OrbiMed, plots D2C-to-pharmacy push and Gulf entry
- HUL trims permanent staff 8.6% to 7,499 in FY26 as demand stays sluggish
- HUL cuts permanent staff 8.6% to 7,499 as demand slowdown forces leaner operating model
- India's $1B nutraceutical market hits trust test as HUL-OZiva deal signals consolidation